New drug cocktail shows promise for rare blood cancer
NCT ID NCT07261163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a combination of three drugs (obinutuzumab, zanubrutinib, and lenalidomide) as a first treatment for people with mantle cell lymphoma who have not had any prior therapy. About 37 adults aged 18 to 80 will receive the drugs, and those at higher risk may also get CAR-T cell therapy. The goal is to see how well this approach controls the cancer and whether it can lead to a complete response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300020, China
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Smartwatches track hidden heart risk in blood cancer patients